Literature DB >> 21927698

Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index.

Chunwoo Lee1, Dalsan You, Junsoo Park, In Gab Jeong, Cheryn Song, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim.   

Abstract

PURPOSE: To assess the validity of the 2009 TNM classification for renal cell carcinoma (RCC) and compare its ability to predict survival relative to the 2002 classification.
MATERIALS AND METHODS: We identified 1,691 patients who underwent radical nephrectomy or partial nephrectomy for unilateral, sporadic RCC between 1989 and 2007. Cancer-specific survival was estimated by the Kaplan-Meier method and was compared among groups by the log-rank test. Associations of the 2002 and 2009 TNM classifications with death from RCC were evaluated by Cox proportional hazards regression models. The predictive abilities of the two classifications were compared by using Harrell's concordance (c) index.
RESULTS: There were 234 deaths from RCC a mean of 38 months after nephrectomy. According to the 2002 primary tumor classification, 5-year cancer-specific survival was 97.6% in T1a, 92.0% in T1b, 83.3% in T2, 61.9% in T3a, 51.1% in T3b, 40.0% in T3c, and 33.6% in T4 (p for trend<0.001). According to the 2009 classification, 5-year cancer-specific survival was 83.2% in T2a, 83.8% in T2b, 62.6% in T3a, 41.1% in T3b, 50.0% in T3c, and 26.1% in T4 (p for trend<0.001). The c index for the 2002 primary tumor classification was 0.810 in the univariate analysis and increased to 0.906 in the multivariate analysis. The c index for the 2009 primary tumor classification was 0.808 in the univariate analysis and increased to 0.904 in the multivariate analysis.
CONCLUSIONS: Our data suggest that the predictive ability the 2009 TNM classification is not superior to that of the 2002 classification.

Entities:  

Keywords:  Kidney neoplasms; Mortality; Neoplasm staging; Prognosis; Renal cell carcinoma

Year:  2011        PMID: 21927698      PMCID: PMC3162217          DOI: 10.4111/kju.2011.52.8.524

Source DB:  PubMed          Journal:  Korean J Urol        ISSN: 2005-6737


  27 in total

1.  Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma.

Authors:  Vincenzo Ficarra; Luigi Schips; François Guillè; Guorong Li; Alexandre De La Taille; Tommaso Prayer Galetti; Luca Cindolo; Giacomo Novara; Richard E Zigeuner; Emiliano Bratti; Jacques Tostain; Vincenzo Altieri; Claude C Abbou; Walter Artibani; Jean-Jacques Patard
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

2.  T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas.

Authors:  Stephen M Bonsib
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

3.  Renal cell carcinoma guideline.

Authors:  Börje Ljungberg; Damian C Hanbury; Marcus A Kuczyk; Axel S Merseburger; Peter F A Mulders; Jean-Jacques Patard; Ioanel C Sinescu
Journal:  Eur Urol       Date:  2007-03-28       Impact factor: 20.096

4.  Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?

Authors:  Ofer N Gofrit; Amos Shapiro; Galina Pizov; Ezekiel H Landau; Ran Katz; Kevin C Zorn; Dov Pode
Journal:  J Urol       Date:  2007-05       Impact factor: 7.450

5.  Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome.

Authors:  Vincenzo Ficarra; Giacomo Novara; Massimo Iafrate; Livio Cappellaro; Emiliano Bratti; Filiberto Zattoni; Walter Artibani
Journal:  Eur Urol       Date:  2006-07-28       Impact factor: 20.096

6.  Reassessing the current TNM lymph node staging for renal cell carcinoma.

Authors:  Carlo Terrone; C Cracco; F Porpiglia; E Bollito; C Scoffone; M Poggio; A Berruti; F Ragni; M Cossu; R M Scarpa; S Rocca Rossetti
Journal:  Eur Urol       Date:  2005-12-20       Impact factor: 20.096

7.  pT2 classification for renal cell carcinoma. Can its accuracy be improved?

Authors:  Igor Frank; Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Eugene D Kwon; Horst Zincke
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

8.  Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma.

Authors:  Haytham H Dimashkieh; Christine M Lohse; Michael L Blute; Eugene D Kwon; Bradley C Leibovich; John C Cheville
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

9.  Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.

Authors:  Tobias Klatte; Jean-Jacques Patard; Rakhee H Goel; Mark D Kleid; Francois Guille; Bernard Lobel; Clement-Claude Abbou; Alexandre De La Taille; Jacques Tostain; Luca Cindolo; Vincenzo Altieri; Vincenzo Ficarra; Walter Artibani; Tommaso Prayer-Galetti; Ernst Peter Allhoff; Luigi Schips; Richard Zigeuner; Robert A Figlin; Fairooz F Kabbinavar; Allan J Pantuck; Arie S Belldegrun; John S Lam
Journal:  J Urol       Date:  2007-05-22       Impact factor: 7.450

Review 10.  The process for continuous improvement of the TNM classification.

Authors:  Mary K Gospodarowicz; Daniel Miller; Patti A Groome; Frederick L Greene; Pamela A Logan; Leslie H Sobin
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

View more
  3 in total

1.  Multiple muscle metastases of the renal cell carcinoma after radical nephrectomy.

Authors:  Berhan Pirimoglu; Hayri Ogul; Abdullah Kisaoglu; Leyla Karaca; Aylin Okur; Mecit Kantarci
Journal:  Int Surg       Date:  2015-04

2.  Pancreatic secondary lesions from renal cell carcinoma.

Authors:  Lucia Moletta; Anna Caterina Milanetto; Valter Vincenzi; Rita Alaggio; Sergio Pedrazzoli; Claudio Pasquali
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

3.  Time trends in service provision and survival outcomes for patients with renal cancer treated by nephrectomy in England 2000-2010.

Authors:  Ray C J Hsu; Matthew Barclay; Molly A Loughran; Georgios Lyratzopoulos; Vincent J Gnanapragasam; James N Armitage
Journal:  BJU Int       Date:  2018-04-20       Impact factor: 5.588

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.